Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) EPS (Weighted Average and Diluted) (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed EPS (Weighted Average and Diluted) for 16 consecutive years, with $0.08 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 147.06% to $0.08 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.7, a 69.96% increase, with the full-year FY2025 number at -$0.7, down 16.67% from a year prior.
  • EPS (Weighted Average and Diluted) was $0.08 for Q4 2025 at Anika Therapeutics, up from -$0.16 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.11 in Q4 2023 to a low of -$2.03 in Q3 2024.
  • A 5-year average of -$0.19 and a median of -$0.2 in 2022 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): crashed 1066.67% in 2022, then soared 426.47% in 2023.
  • Anika Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.4 in 2021, then rose by 15.0% to -$0.34 in 2022, then skyrocketed by 426.47% to $1.11 in 2023, then crashed by 115.32% to -$0.17 in 2024, then skyrocketed by 147.06% to $0.08 in 2025.
  • Per Business Quant, the three most recent readings for ANIK's EPS (Weighted Average and Diluted) are $0.08 (Q4 2025), -$0.16 (Q3 2025), and -$0.28 (Q2 2025).